Currently, Ovid Therapeutics Inc [OVID] is trading at $1.49, up 6.43%. An important factor to consider is whether the stock is rising or falling in short-term value. The OVID shares have gain 14.62% over the last week, with a monthly amount drifted -8.59%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on October 09, 2025, and set its price target to $7. Oppenheimer downgraded its rating to a Perform. B. Riley Securities initiated its recommendation with a Buy and recommended $9 as its price target on April 30, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on April 29, 2024, and assigned it a price target of $9. In a note dated April 05, 2024, Wedbush initiated an Outperform rating and provided a target price of $8 on this stock.
This stock has fluctuated between a low of $0.24 and a high of $2.01 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $1.49 at the most recent close of the market. An investor can expect a potential return of 34.23% based on the average OVID price forecast.
Analyzing the OVID fundamentals
Trailing Twelve Months sales for Ovid Therapeutics Inc [NASDAQ:OVID] were 6.61M which represents -23.70% decline. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -6.18%, Pretax Profit Margin comes in at -5.5%, and Net Profit Margin reading is -5.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.64 and Total Capital is -0.72. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4217 points at the first support level, and at 1.3533 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5567, and for the 2nd resistance point, it is at 1.6233.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ovid Therapeutics Inc [NASDAQ:OVID] is 4.24. On the other hand, the Quick Ratio is 4.24, and the Cash Ratio is 3.03. Considering the valuation of this stock, the price to sales ratio is 16.05, the price to book ratio is 2.37.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Feb 26 ’25 when 5279.0 shares were sold. CBFO, Rona Jeffrey A completed a deal on Feb 26 ’25 to sell 3902.0 shares. Meanwhile, President and COO ALEXANDER MARGARET A. bought 6810.0 shares on Jan 27 ’25.
